Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (35)
NITAG documentation (1612)
Reports (58)
SAGE documentation (226)
Scientific publications (114)
Systematic reviews (SYSVAC) (2936)
Regions
Africa (289)
Americas (772)
Eastern Mediterranean (52)
Europe (719)
Global (1)
South-East Asia (82)
Western Pacific (209)
Diseases
Chikungunya (10)
Cholera (35)
COVID-19 (1544)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (81)
Ebola (17)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (162)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (507)
Influenza (601)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (30)
Measles (136)
Meningococcal disease (150)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (109)
Pneumococcal disease (286)
Poliomyelitis (88)
Q fever (1)
Rabies (31)
Rotavirus (118)
RSV (Respiratory syncytial virus) (56)
Rubella (65)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (62)
Tick-borne encephalitis (12)
Tuberculosis (78)
Typhoid (27)
Varicella (74)
Yellow fever (43)
Zika (1)
Show more
4981 results found
2025
6th GNN meeting record of discussion
2025
∙
WHO AFRO
Mpox vaccination toolkit
2025
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response
2025
∙
SAGE
WHO guidance on the use of licensed human influenza A(H5) vaccines for the interpandemic and emergence periods
2025
∙
National Advisory Group on Immunisation (NAGI)
RSV vaccination recommendation during pregnancy
2025
∙
National Advisory Group on Immunisation (NAGI)
Catch-up dose of Measles-Rubella to children at 9 years of age
2025
∙
ATAGI
ATAGI statement: Counterfeit Rabies vaccine (Abhayrab®) reported in India: Guidance for travellers and healthcare providers
2025
∙
ATAGI
ATAGI statement on the importance and safety of Hepatitis B vaccine at birth
2025
∙
ATAGI
Summary of the ATAGI 116th meeting, 15 October 2025
2025
∙
STIKO
Decision and scientific rationale for extending the indication for herpes zoster vaccinations with the adjuvanted subunit vaccine for individuals aged 18+ years with an increased risk of developing herpes zoster
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register